Physician profile
Anna Owczarski
NPI 1154718856
$5,226.53
in general payments reported to CMS, 2019-2025
30 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $1,046 · 2023: $1,549 · 2024: $1,008 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,617.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $828.87 | 2021-2025 | Repatha, Prolia, Repatha |
| Novo Nordisk INC | $734.15 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $665.42 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $661.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $519.42 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.84 | 2021-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $290.58 | 2021-2024 | |
| Dexcom, INC. | $180.37 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $119.63 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $102.56 | 2021 | |
| Pfizer INC. | $97.29 | 2021-2024 | |
| Esperion Therapeutics, INC. | $90.80 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $87.12 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Alnylam Pharmaceuticals INC. | $82.71 | 2023-2024 | Onpattro, Givlaari |
| Exact Sciences Corporation | $73.21 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $57.37 | 2024 | Opsumit, Uptravi |
| Pulmonx Corporation | $43.13 | 2022 | |
| Astellas Pharma US INC | $40.85 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $32.06 | 2024 | Vpriv |
| Tolmar, INC. | $30.80 | 2024-2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $29.20 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.98 | 2021-2022 | |
| Nevro Corp. | $20.39 | 2023 | Senza |
| Daiichi Sankyo INC. | $20.27 | 2024 | Injectafer |
| Eisai INC. | $20.08 | 2025 | |
| Adlon Therapeutics L.P. | $17.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.15 | 2022 | |
| Ibsa Pharma INC. | $15.66 | 2023 | Tirosint, Licart |
| Seqirus USA INC | $14.51 | 2022 | |
| Inari Medical, INC. | $14.06 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Owczarski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.